Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
Japan’s economy revitalization minister Ryosei Akazawa said on September 30 that Tokyo has secured most-favored-nation (MFN) treatment for pharmaceutical tariffs under its trade arrangements with Washington, dismissing concerns over potentially higher duties. Speaking to reporters after a government briefing at…
To read the full story
Related Article
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
September 29, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- LDP Tariff Task Force Broadly OKs First Proposal
April 22, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
REGULATORY
- LDP Panel Approves Honebuto Proposal on Preventive Healthcare
June 2, 2026
- LDP Patch League to Seek Drug Price Support in Honebuto Proposal
June 2, 2026
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- Japan Enacts Reform Bill Paving Way for OTC-Like Drug Charges
June 1, 2026
- Four Pharma Secondees Join AMED Drug Discovery Initiative
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…